Agendia Presents Data at ASCO 2022 Pointing to New Signature ImPrint Immunotherapy Prediction and Expansion of Proprietary Genomic Tests’ Utility to Identify Patients Who Will Benefit Most from Specific Treatments

IRVINE, Calif. & AMSTERDAM–(BUSINESS WIRE)– Agendia, Inc., a commercial-stage company focused on improving outcomes for breast cancer patients worldwide by providing physicians and patients with next-generation diagnostic and information solution…